CASI Pharmaceuticals’ (CASI) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of CASI Pharmaceuticals (NASDAQ:CASI) in a research note issued to investors on Tuesday. The brokerage currently has a $5.00 price target on the biotechnology company’s stock.

Separately, Maxim Group set a $4.00 target price on shares of CASI Pharmaceuticals and gave the stock a buy rating in a report on Tuesday, November 14th.

Shares of CASI Pharmaceuticals (NASDAQ CASI) traded up $0.06 during trading on Tuesday, reaching $3.85. 306,430 shares of the company traded hands, compared to its average volume of 250,173. The company has a market cap of $238.55, a P/E ratio of -32.08 and a beta of 1.08. CASI Pharmaceuticals has a one year low of $0.91 and a one year high of $4.84.

CASI Pharmaceuticals (NASDAQ:CASI) last issued its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.01. equities research analysts expect that CASI Pharmaceuticals will post -0.13 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “CASI Pharmaceuticals’ (CASI) Buy Rating Reaffirmed at HC Wainwright” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this story can be read at https://www.dispatchtribunal.com/2018/01/17/casi-pharmaceuticals-casi-buy-rating-reaffirmed-at-hc-wainwright.html.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.

Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply